

Original Article
Asian Pacific Journal of Tropical Medicine
journal homepage: www.apjtm.org

doi: 10.4103/1995-7645.269905
Impact factor: 1.77

Molecular characterization and subtyping of *Blastocystis* in urticarial patients in Turkey

Merve Aydin[1,2]✉, Mustafa Yazici[3], Mehtap Demirkazik[4], Ismail Soner Koltas[4], Aytekin Cikman[1], Baris Gulhan[1], Tugce Duran[5,6], Aysun Yilmaz[7], Murat Kara[1]

[1]*Department of Medical Microbiology, Faculty of Medicine, Erzincan University, Erzincan, Turkey*
[2]*Department of Medical Microbiology, Faculty of Medicine, KTO Karatay University, Konya, Turkey*
[3]*Department of Dermatology, Faculty of Medicine, Erzincan University, Erzincan, Turkey*
[4]*Department of Medical Parasitology, Faculty of Medicine, Çukurova University, Adana, Turkey*
[5]*Department of Medical Genetics, Faculty of Medicine, KTO Karatay University, Konya, Turkey*
[6]*Department of Medical Genetics and Molecular Biology, Institute of Health Sciences, Kocaeli University, Kocaeli, Turkey*
[7]*Department of Medical Microbiology, Institute of Health Sciences, Erzincan University, Erzincan, Turkey*

ARTICLE INFO

Article history:
Received 1 April 2019
Revised 10 August 2019
Accepted 10 October 2019
Available online 30 October 2019

Keywords:
Urticaria
Blastocystis
Subtypes
PCR
DNA sequence analysis

ABSTRACT

Objective: To investigate *Blastocystis*' etiologic role and association with gastrointestinal symptomatology in acute and chronic urticaria patients and to identify *Blastocystis* subtypes responsible for urticaria.

Methods: The study included urticaria patients and healthy individuals that presented to our polyclinic between June 2015 and May 2017. The participants were assigned into Group Ⅰ (137 patients), subdivided into acute (72) and chronic urticaria patients (65), and Group Ⅱ (129 control individuals). *Blastocystis* presence was investigated by native-Lugol examination, trichrome staining, PCR using sequence tagged site primers, and DNA sequencing analysis. The phylogenetic tree was constructed.

Results: The native-Lugol and trichrome staining methods revealed that 16 patients (16/133, 12.0%) had *Blastocystis*-positive stool samples, of which seven samples (7/133, 5.3%) belonged acute and nine (9/133, 6.8%) to chronic urticaria patients. Concerning *Blastocystis* subtypes, of the acute urticaria patients, three had subtype 1 (ST1), one had ST2, and three had ST3. Of the chronic urticaria patients, one had ST1 and eight had ST3. *Blastocystis* positivity was detected in two control individuals (2/123, 1.6%), both being ST3. All subtypes identified by PCR were confirmed by the sequencing analysis. The acute and chronic urticaria groups showed no statistically significant differences for *Blastocystis* positivity (P=0.60) and subtype distribution (P=0.15). A statistically significant difference was found between the urticaria patients and the controls for *Blastocystis* positivity (P<0.01), but not for subtype distribution (P=0.67) or for *Blastocystis* presence and gastrointestinal complaints.

Conclusions: This study on *Blastocystis* subtype distribution among Turkish urticaria patients showed results consistent with the literature. It was concluded that *Blastocystis* should be kept in mind in patients with urticaria.

1. Introduction

Blastocystis is defined as one of the most commonly found single-celled eukaryotes in human stool specimens and affects humans and a wide range of animals worldwide[1,2]. *Blastocystis* has a complex taxonomic history. In the past 20 years, it was considered as a

✉Corresponding author: Merve Aydin, Department of Medical Microbiology, Faculty of Medicine, KTO Karatay University, Konya 42020, Turkey.
Tel: +90 (332) 444 1251/7270
Fax: +90 (332) 202 0044
E-mail: merve.aydin@karatay.edu.tr; mervegazi@yahoo.com.tr
Foundation project: This project was financially supported by the Scientific Project Unit of Erzincan University (Project No: SAG-A-240215-0128).

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

©2019 *Asian Pacific Journal of Tropical Medicine* Produced by Wolters Kluwer- Medknow. All rights reserved.

How to cite this article: Aydin M, Yazici M, Demirkazik M, Koltas IS, Cikman A, Gulhan B, et al. Molecular characterization and subtyping of *Blastocystis* in urticarial patients in Turkey. Asian Pac J Trop Med 2019; 12(10): 450-456.

fungus, a sporozoan, or even a cyst of another organism at different points of its history[2,3]. Although molecular phylogenetic approaches have been applied for a long time, *Blastocystis* has just recently been clearly classified in the complex evolutionary combination of heterotrophic and photosynthetic protozoa, Stramenopiles[4].

The prevalence of *Blastocystis* varies from one country to another and even in different communities within the same country, reaching 20% in industrialized countries and exceeding 50% in developing countries[5-7]. In a recent study, the prevalence of *Blastocystis* in a group of children living in the rural parts of Senegal was reported to be 100%[7]. These differences may be associated with hygiene standards, waste disposal, close animal contact, and contaminated food or water consumption since it is thought that transmission is through the fecal-oral route, and cyst is the only form[5,6]. However, the extent to which human-human, human-animal and animal-human transmission occurrence remains controversial[6,7].

Based on the comparison of small subunit (SSU) rRNA gene sequences of the genus *Blastocystis*, at least 17 different ribosomal strains were classified as undisputed distinct species, also called subtypes (ST)[7,8]. Nine of these 17 subtypes (ST1 to ST9) are found in humans. In 90% of human epidemiological studies, one of the four subtypes (ST1-ST4) is observed, with ST3 being the dominant subtype[7-9]. In contrast, the less frequent subtypes for humans (ST5-ST8) are more common in other hosts, with ST5 being found in hoofed animals, and ST6, ST7 and ST8 in primates[3,7,9]. Rare subtypes detected in humans may be of zoonotic origin, and there are some evidences to support this: ST8 has been reported in zookeepers working with non-human primates, and ST5 in those dealing with pigs. ST9 has not been seen in any host other than humans[8].

The debate on the pathogenesis of *Blastocystis* remains controversial. Since *Blastocystis* is common both in healthy individuals and in patients suffering from gastrointestinal symptoms. Currently, it is not possible to distinguish colonization from infection[10,11]. The clinical characteristics of the disease attributed to this pathogen are not specific and include nausea, abdominal pain, gas, acute or chronic diarrhea, irritable bowel syndrome, angioedema, and urticaria[12,13]. One of the current hypotheses is that the variations in the clinical outcomes may be due to the differences in the subtypes[14].

Urticaria (hives) is a common disease that occurs in 15%-25% of individuals at any stage of life[15,16]. Urticaria is usually classified as acute, chronic or physical depending on the duration of symptoms and the presence or absence of stimuli. Acute urticaria is characterized by recurrent wheals for a maximum of six weeks with or without angioedema, whereas chronic urticaria refers to the recurrence of lesions for longer than six weeks[16,17]. The most common causes of urticaria (with or without angioedema) are drugs, food, viral infections, pesticides, and contact allergens, especially latex hypersensitivity. In 50% of patients with urticaria, the cause of the disease cannot be determined (idiopathic urticaria)[15,17]. Studies investigating the etiological role of *Blastocystis* in urticaria are limited, with most presenting case reports. The current study aimed to investigate the etiologic role of *Blastocystis* in acute and chronic urticaria patients and determine the responsible subtypes and their relation with gastro-intestinal symptomatology.

2. Materials and methods

2.1. Patients and study design

This prospective study was carried out in the Dermatology Polyclinic of Erzincan University Training and Research Hospital in Turkey between June 2015 and May 2017. A total of 266 participants were included in the study and assigned into two groups as Group Ⅰ (137 patients) and Group Ⅱ (129 control individuals). Group Ⅰ was further divided into two sub-groups as Group Ⅰ A consisting of 72 patients with acute urticaria (wheals of less than six weeks' duration) and Group Ⅰ B comprising 65 patients with chronic urticaria (wheals of more than six weeks' duration). Group Ⅱ was consisted of 129 healthy individuals that presented to our hospital for routine health control without any particular complaint. Patients satisfying the following conditions were considered eligible for inclusion in the study: (1) the occurrence of angioedema with spontaneous wheals for six weeks or longer; (2) volunteering to participate in this study and providing written informed consent. The exclusion criteria were as follows: (1) pregnancy and breastfeeding; (2) presence of personal and family history of asthma, allergy or nasal allergy, or hypersensitivity to particular foods and drugs; (3) diagnosis of any systemic disease and other types of urticaria, such as physical urticaria, hereditary angioedema, and cholinergic urticaria; (4) complications with other skin disorders that interfere with efficacy evaluations; (5) having taken corticosteroids or immunomodulators within the past four weeks or antihistamines within the past three days; (6) presence of fever, arthralgia, or insect bites prior to the onset of symptoms.

2.2. Ethical approval and questionnaire

This study protocol was approved by the Ethics Committee of Erzincan University, Erzincan, Turkey (Approval No: 01/03, Date: 06.02.2015). Prior to data collection, the objectives, possible advantages and disadvantages of the study were explained to all participants. Written informed consent was obtained from each participant and the parents of children under 18 years of age. The participants were asked to complete a standard questionnaire to reveal information on their age, gender, type of water supply,

presence of domestic animals, and presence of gastrointestinal complaints (gas, nausea, vomiting, abdominal pain, diarrhea, constipation, bloating, and weight loss). The face-to-face interview method was used for the completion of the questionnaire.

2.3. Stool samples and microscopy

Stool samples taken from the patients and the control group were sent to the microbiology laboratory to be examined for the presence of parasites. The samples were aliquoted for DNA extraction alongside conventional stool examination by microscopy. The stool samples were analyzed immediately using native-Lugol and modified formol-ether concentration methods, and in parallel with these examinations, trichrome and kinyoun acid fast staining was performed. *Blastocystis*-positive samples were cultured in Jones's medium and checked by light microscopy to record morphologic features on day 3 and day 5 as described previously[18]. All of the patients that were found to have *Blastocystis* were treated with 750 mg metronidazole (10 mg/kg/dose in children) orally, three times over a period of 10 d. The stool samples were collected once more after treatment and the patients' response to treatment was recorded.

2.4. DNA isolation and subtyping

The genomic DNA was extracted from all stool samples with *Blastocystis* positivity using a QIAamp DNA stool mini kit (Qiagen, Hilden, Germany) according to the manufacturer's recommendations. The DNA concentrations were determined using a NanoDrop ND-1000 spectrophotometer (ThermoScientific, Wilmington, DE, USA) and stored at -20 ℃ for further experiment.

The PCR was performed using seven subtype-specific sequence tagged site primers [SB83 (351 bp) for ST1, SB340 (704 bp) for ST2, SB227 (526 bp) for ST3, SB337 (487 bp) for ST4, SB336 (317 bp) for ST5, SB332 (338 bp) for ST6, and SB155 (650 bp) for ST7] for the subtyping of *Blastocystis* species[18]. *Blastocystis hominis* Brumpt (ST1, ATCC®50752™) was used as the reference strain. Amplification reactions were performed in a total volume of 25 µL containing 12.5 µL of DreamTaq PCR Master Mix (2×) (Thermo Scientific, Waltham, MA, USA), 1.5 µL of each primer (10 pmol), and 2-5 µL of DNA. The PCR consisted of initial denaturation at 94 ℃ for 5 min, followed by 40 cycles including denaturation at 94 ℃ for 1 min, annealing at 56 ℃ for 1 min, elongation at 72 ℃ for 1.5 min, and a final extension at 72 ℃ for 10 min.

2.5. PCR amplification and DNA sequencing

The 600 bp barcoding region of the *SSU–rRNA* gene of *Blastocystis* was amplified using RD5 (5'-ATC TGG TTG ATC CTG CCAG T-3') and BhRDr (5'- GAG CTT TTT AAC TGC AAC G -3') primers[19]. The PCR reaction mixtures (25 mL of total volume) consisted of the 12.5 µL DreamTaq PCR Master Mix (2×) (Thermo Scientific, Waltham, MA, USA), 1.5 µL of each primer (10 pmol), and 2-5 µL of the DNA. PCR was carried out using the following conditions: initial denaturation at 94 ℃ for 1 min, followed by 40 cycles of denaturation at 94 ℃ for 1 min, annealing at 59 ℃ for 1 min, elongation at 72 ℃ for 1 min, and a final extension at 72 ℃ for 10 min. To verify the presence of a single band and the size of the amplified products (approximately 600 bp), the PCR products and 100 bp DNA marker (GeneRuler 100 bp DNA ladder, Thermo Fisher Scientific, USA) were electrophoresed in 2% agarose gels in a Tris-borate-EDTA (TBE) buffer, stained with ethidium bromide, and photographed under a UV transilluminator.

The PCR products were purified using the Agencourt AMPure XP Beads PCR purification kit (Beckman Coulter, CA, USA) and sequenced in both directions using the PCR primers (RD5 and BhRDr). DNA sequencing reactions were performed using the BigDye® Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City, CA, USA) and analyzed using the ABI PRISM 3130 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).

2.6. Phylogenetic analysis

The *SSU–rRNA* sequences were compared to those available in the GenBank nucleotide database using BLAST tool obtained from the website of the National Center for Biotechnology Information (NCBI). The results of two-directional sequencing were edited by the BioEdit software and aligned with the previously published data of the *SSU–rRNA* gene of *Blastocystis* isolates using the ClustalW program. Then, a phylogenetic tree was constructed with the neighbor-joining method using the MEGA software version 7.0, and the molecular distances were estimated by the number of differences model[20]. All the gaps were excluded from the analysis, and branch support was ascertained using 1 000 bootstrap replicates. *Proteromonas lacerate* (AY224080) was used as the out-group.

2.7. Statistical analysis

The statistical software SPSS (IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp. Released 2011) was used to analyze the data. For discrete and continuous variables, descriptive statistics (mean, standard deviation, median, minimum value, maximum value, and percentile) were obtained. In addition, homogeneity of variance, which is one of the prerequisites of parametric tests, was checked through Levene's test. The assumption

of normality was tested via the Shapiro-Wilk test. To compare the differences between the two groups, the Student's *t*-test was used when the parametric test prerequisites were fulfilled, and the Mann Whitney-U test was conducted when such prerequisites were not satisfied. The relationships between the categorical variables were analyzed by Fisher's exact and *chi*-square tests. In cases where the expected frequencies were less than 20%, the Monte-Carlo simulation method was employed to include these frequencies in the evaluation. $P<0.05$ were considered to be statistically significant.

3. Results

3.1. Demographic and baseline characteristics of the study population

Of the 308 patients initially screened, 266 were included in the study. The Consolidated Standards of Reporting Trials (CONSORT) flowchart diagram is shown in Figure 1. A total of 10 samples, two in the acute urticaria group, two in the chronic urticaria group and six in the control group, were excluded from analysis due to either insufficient sample of stool or destroyed samples. The urticaria group comprised 50 (37.6%) male and 83 (62.4%) female patients. The age of the urticaria group ranged from 2 to 78 years, with the mean age being calculated as (41.6±17.1) years. Of the control group, 52 (42.3%) were male and 71 (57.7%) were female. The age range of the control group was 17 to 86 years, and the mean age was (37.3±19.5) years. There was no statistically significant difference between the groups in terms of age ($P=0.84$). Seventy patients (70/133, 52.6%) had acute and 63 (63/133, 47.4%) had chronic urticaria. Of the patients with acute urticaria, 29 (29/70, 41.4%) were male and 41 (41/70, 58.6%) were female, the mean age was (38.9±17.6) years. Of the patients with chronic urticaria, 21 (21/63, 33.3%) were male and 42 (42/63, 66.7%) were female with a mean age of (44.7±16.2) years.

3.2. Prevalence and subtype distribution of Blastocystis among the groups

In the patient group, *Blastocystis* was found in 16 of stool samples (16/133, 12.0%) using native-Lugol and trichrome staining methods. Using the culture technique, 15 samples were identified as vacuolar (15/16, 93.8%) and one as the granular (1/16, 6.2%) form of the parasite. The *Blastocystis*-positive stool sample of one patient also had *Giardia* positivity. Except *Blastocystis* and *Giardia*, no other parasite was detected. Of the *Blastocystis*-positive patients, seven were in the acute (7/133, 5.3%) and nine were in the chronic (9/133, 6.8%) urticaria subgroups.

Of the seven acute urticaria patients with *Blastocystis* positivity, three had ST1, one had ST2, and three had ST3. Of the nine chronic urticaria patients with *Blastocystis* positivity, one had ST1 and eight had ST3. There was no statistically significant difference in *Blastocystis* positivity ($P=0.60$) nor in the distribution of subtypes ($P=0.15$), between the acute and chronic urticaria subgroups. In the control group, *Blastocystis* positivity was found in two of the 123 healthy individuals (2/123, 1.6%), and both isolates were identified as ST3. Both isolates (100%) were detected to be the vacuolar form of the parasite using the culture technique. A statistically significant difference was observed between the urticaria patients and the control group in terms of *Blastocystis* positivity ($P<0.01$), but there



Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flowchart diagram of the study.

was no such difference in the distribution of subtypes, (P=0.66) (Table 1). All subtypes identified by PCR were confirmed by the sequence analysis (Figure 2).

Table 1. Comparison of demographic and epidemiological data between the urticaria and control groups.

Factors		Urticaria (n=133)	Control (n=123)	P value
Age (Mean±SD)		41.6±17.1	37.3±19.5	0.84$^{\yen}$
Gender	Male	50/37.6	52/42.3	0.45$^{\Omega}$
Blastocystis	Positive	16/12.0	2/1.6	<0.01$^{**\Omega}$
Animal contact	Yes	22/16.5	10/8.1	0.04$^{*\Omega}$
Drinking water	Mains	117/88.0	112/91.1	0.42$^{\Omega}$
	Spring	16/12.0	11/8.9	

$^{\Omega}$*Chi* Square test; $^{\yen}$Mann Whitney-U test; *,** means there is significant difference.

Table 2. Comparison of *Blastocystis* positivity and demographic, clinical and epidemiological data in the urticaria group [n(%)].

Factors		Patients with urticaria (n=133)	*Blastocystis* positivity (n=16)	P value$^{\Omega}$
Gender	Male	50/37.6	9/18.0	0.10
Itching	Yes	133/100	16/100	0.54
Gas	Yes	69/51.9	11/15.9	0.15
Bloating	Yes	70/52.6	9/12.9	0.76
Nausea	Yes	33/24.8	6/18.2	0.21
Abdominal pain	Yes	45/33.8	5/11.1	0.82
Constipation	Yes	62/46.6	5/8.1	0.19
Diarrhea	Yes	23/17.3	3/13.0	0.87
Vomiting	Yes	11/8.3	1/9.1	0.75
Weight loss	Yes	19/14.3	1/5.3	0.33
Animal contact	Yes	22/16.5	2/9.1	0.64
Drinking water	Mains	117/88.0	14/12.0	0.95
	Spring	16/12.0	2/12.5	

$^{\Omega}$*Chi* Square test.

3.3. Relationship between Blastocystis and demographic, clinical and epidemiological factors

Of the patients with *Blastocystis*-positive stool samples, nine were male and seven were female. In the control group, the two having *Blastocystis* positivity were male. No statistically significant difference was found between *Blastocystis* positivity and gender in the patient and control groups (P=0.10, P=0.10) (Table 2).

Of the 133 patients, 88.0% (n=117) reported using mains water and 12.0% (n=16) spring water as drinking water. Fourteen of the 16 patients that had *Blastocystis* positivity were found to use mains water for drinking. In the control group, 112 of 123 individuals (91.1%) used mains water and 11 (8.9%) spring water. Both healthy volunteers with *Blastocystis* positivity were reported to use mains water as drinking water. However, there was no statistically significant difference in the source of drinking water between cases with and without *Blastocystis* positivity in the patient and control groups (P=0.95, P=0.66) (Table 2).

Animal contact was found in 22 of 133 patients and 10 of 123 healthy controls. While two of the 16 patients with *Blastocystis* positivity had animal contact, neither of the two healthy controls reported such contact. There was no statistical difference between the presence of *Blastocystis* and animal contact (P=0.64, P=0.67) (Table 2).

In the patient group, the symptoms of individuals with *Blastocystis* positivity were as follows: itching (16/16), gas (11/16), bloating (9/16), nausea (6/16), abdominal pain (5/16), constipation (5/16), diarrhea (3/16), vomiting (1/16), and weight loss (1/16). There was no statistically significant difference between the presence of *Blastocystis* and any of these symptoms (Table 2). Sixteen

Figure 2. Neighbor-joining tree based on the SSU-rRNA region sequences showing the phylogenetic relationship between *Blastocystis* isolates. The bootstrap values were computed over 1 000 replicates. Acute urticaria, chronic urticaria, and control isolates are indicated by “AU”, “CU”, and “C”, respectively. The sequences of strains isolated from the patients with acute urticaria, those with chronic urticaria and the control group are represented by a black triangle, black square, and black circle, respectively. The white squares represent the reference sequences from each subtype. *Proteromonas lacerate* (AY224080) was used as an out-group during phylogenetic analysis. Scale bar: 0.02 nucleotide substitutions per alignment position.

patients with *Blastocystis*-positive stool samples and two control individuals were treated with 750 mg of metronidazole orally for 10 d. No parasites were detected in the stool samples of any of these 18 individuals after two weeks. The primary outcome of this study was that in *Blastocystis*-positive patients, urticaria lesions disappeared after metronidazole treatment, revealing the possibility of a relationship between urticaria and *Blastocystis*, independent of gastrointestinal symptomatology and subtype.

4. Discussion

In this study, of the seven acute urticaria patients with *Blastocystis* positivity, three had ST1, one had ST2, and three had ST3, and among the nine *Blastocystis*-positive patients with chronic urticaria, one ST1 and eight ST3 were identified. There was no statistically significant difference between the patients with acute and chronic urticaria in terms of *Blastocystis* positivity or subtype distribution (P=0.60, P=0.15). However, a statistically significant difference was found between the urticaria patients and the control group in terms of *Blastocystis* positivity while subtype distribution did not significantly differ between the two groups. In the control group, *Blastocystis* positivity was detected in two of the 123 individuals, and both isolates were identified as ST3. Research on *Blastocystis* subtypes in urticaria cases has been undertaken in different parts of the world, and the predominant subtype has been shown to be ST3, and some of the studies in the literature have considered urticaria as a complication of *Blastocystis*[21-23]. In a study conducted with 54 urticaria cases, 18 acute (33.3%) and 36 chronic (66.7%), Abdel Hameed *et al*. reported that *Blastocystis* positivity was present in 33 (61.1%) patients. Of these 33 patients, 21 were symptomatic and 12 were asymptomatic. The authors subtyped all *Blastocystis* isolates in both groups as ST3[21]. In addition, in 2015, Casero *et al*. detected *Blastocystis* positivity in 67 of 270 patients from Argentina. The symptomatic group consisted of 39 patients, comprising 18 urticaria cases, 18 individuals with non-specific gastrointestinal symptoms, and 3 with both urticaria and non-specific gastrointestinal symptoms. The asymptomatic group contained 28 individuals. Morphological analysis, DNA extraction, 18S PCR, and DNA sequence analysis were performed on the *Blastocystis* isolates. Of the 67 *Blastocystis* isolates, 49 were identified as ST3 (71.6%), distributed as 71.4% (n=35) in the symptomatic group and 28.6% (n=14) in the asymptomatic group. Furthermore, 10 isolates (14.9%) were defined as ST1, 10 (7.5%) as ST6, and 4 (6.0%) as ST2. Two of 10 ST1 isolates were found in the symptomatic group and eight in the asymptomatic group. Five ST6 isolates were detected in the asymptomatic group. Two of the four ST2 isolates were observed in the symptomatic group and the other two in the asymptomatic group. The authors reported a high rate of ST3 in patients with urticaria and non-specific gastrointestinal symptoms, but there was no statistically significant difference between the symptomatic and asymptomatic groups in terms of subtype distribution[22].

Although only three subtypes (ST1, ST2 and ST3) were obtained in the current study, ST3 was dominant, especially in cases of chronic urticaria. In addition, the absence of animal transitional subtypes, such as ST5 or ST7, indicates that these isolates are not of zoonotic origin and have an anthroponotic profile.

In recent years, different *Blastocystis* subtypes have been discussed as having varying pathogenic potential. This possibility was first raised by Clark in 1997[24]. Later in 2001, Kaneda *et al*. reported that ST1, ST2 and ST4 might be responsible for gastrointestinal symptoms[25]. In 2012, Poirier *et al*. suggested that ST7 was correlated with irritable bowel syndrome[4]. Puthia *et al*. stated that in rat epithelial cells, ST4 might induce apoptosis independent of contact, thus increasing epithelial permeability[26]. In 2006, Yan *et al*. found the presence of only ST1 in a group of symptomatic patients. This finding was confirmed in 2013 by El Safadi *et al*, who showed that ST1 was associated with high pathogenicity[27,28]. The pathogenicity of ST4 was presented in a short report by Stensvold *et al*[29].

Urticaria is a heterogeneous group of diseases with a highly variable clinical manifestation and can be caused by a variety of factors. Parasitic diseases, especially *Blastocystis*, have long been considered to be the cause of potential urticaria. It is argued that *Blastocystis* may be a causal factor in the unclarified etiology of urticaria[30].

It has been suggested that aspirin or non-steroidal anti-inflammatory drugs may be a co-factor in the process of *Blastocystis* causing urticaria through a pathogenic route similar to the food-or exercise-induced anaphylactic reaction. To date, very little is known about why some subtypes cause urticaria only in certain patient groups[30,31]. In 2008, Katsarou-Katsari *et al*. detected *Blastocystis* in the stool sample of a patient with acute urticarial lesions and minor gastrointestinal symptoms and identified the isolate as ST3. Although antihistaminic drugs were given, the symptoms of the patient did not regress; thus, an oral metronidazole treatment was started and urticaria lesions were observed to regress after one week. The patient’s gastrointestinal symptoms disappeared, and reexamination of his stool showed no *Blastocystis*.

Similarly, in the current study, all the *Blastocystis*-positive patients responded to the metronidazole treatment and showed no symptoms of urticaria after the treatment[32]. Therefore, our study confirms that *Blastocystis* is a source of infection that must be kept in mind in the etiology of urticaria. In addition, the patients with acute and chronic urticaria were followed up clinically and parasitologically for a period of one year, during which the symptoms disappeared and did not recur. This is an evidence that *Blastocystis* infection may be one of the underlying causes of resistance to urticaria treatment.

In conclusion, our results are consistent with the international literature, demonstrating the relationship between *Blastocystis* presence and urticaria. Considering the limited number of studies on the relationship between *Blastocystis* subtypes and pathogenicity in patients with urticaria, there is a need for comprehensive studies to explore the efficacy of treatment in this patient group in different countries and populations.

Conflict of interest statement

The authors declare that they have no conflicts of interest.

Authors' contributions

M.A., M.Y., M.D. and I.S.K. designed the study, M.A., M.Y., A.C., B.G., A.Y. and M.K. collected samples. M.A., M.D. and T.D. analyzed and interpreted data. M.A, I.S.K. and T.D. contributed to critical revision of the manuscript for important intellectual content and final approval of the manuscript.

References

[1] Wawrzyniak I, Poirier P, Viscogliosi E, Dionigia M, Texier C, Delbac F, et al. *Blastocystis*, an unrecognized parasite: An overview of pathogenesis and diagnosis. *Ther Adv Infect Dis* 2013; **1**(5): 167-178.

[2] El Safadi D, Cian A, Nourisson C, Pereira B, Morelle C, Bastien P, et al. Prevalence, risk factors for infection and subtype distribution of the intestinal parasite *Blastocystis* sp. from a large-scale multi-center study in France. *BMC Infect Dis* 2016; **16**(1): 451.

[3] Stensvold CR, Clark CG. Current status of *Blastocystis*: A personal view. *Parasitol Int* 2016; **65**(5): 763-771.

[4] Poirier P, Wawrzyniak I, Vivarès CP, Delbac F, El Alaoui H. New insights into *Blastocystis* spp.: A potential link with irritable bowel syndrome. *PLoS Pathog* 2012; **8**(3): e1002545.

[5] Alfellani MA, Stensvold CR, Vidal-Lapiedra A, Onuoha ES, Fagbenro-Beyioku AF, Clark CG. Variable geographic distribution of *Blastocytis* subtypes and its potential implications. *Acta Trop* 2013; **126**(1): 11-18.

[6] Ramírez JD, Sánchez LV, Bautista DC, Corredor F, Flórez AC, Stensvold CR. *Blastocystis* subtypes detected in humans and animals from Colombia. *Infect Genet Evol* 2014; **22**: 223-228.

[7] El Safadi D, Gaayeb L, Meloni D, Cian A, Poirier P, Wawrzyniak I, et al. Children of Senegal River Basin show the highest prevalence of *Blastocystis* sp. ever observed worldwide. *BMC Infect Dis* 2014; **14**: 164.

[8] Cian A, El Safadi D, Osman M, Moriniere R, Gantois N, Benamrouz-Vanneste, et al. Molecular epidemiology of *Blastocystis* sp. in various animal groups from two French zoos and evaluation of potential zoonotic risk. *PLoS One* 2017; **12**(1): e0169659.

[9] Clark CG, van der Giezen M, Alfellani MA, Stensvold CR. Recent developments in *Blastocystis* research. *Adv Parasitol* 2013; **82**: 1-32.

[10] Andersen LO, Stensvold CR. *Blastocystis* in health and disease: Are we moving from a clinical to a public health perspective? *J Clin Microbiol* 2016; **54**(3): 524-528.

[11] Stensvold CR. Laboratory diagnosis of *Blastocystis* spp. *Trop Parasitol* 2015; **5**(1): 3-5.

[12] Roberts T, Stark D, Harkness J, Ellis J. Update on the pathogenic potential and treatmet options for *Blastocystis* sp. *Gut Pathog* 2014; **6**: 17.

[13] Micheloud D, Jensen J, Fernandez-Cruz E, Carbone J. Chronic angiodema and *Blastocystis* hominis infection. *Rev Gastroenterol Peru* 2007; **27**(2): 191-193.

[14] Scanlan PD. *Blastocystis*: Past pitfalls and future perspectives. *Trends Parasitol* 2012; **28**(8): 327-334.

[15] Amar SM, Dreskin SC. Urticaria. *Prim Care* 2008; **35**(1): 141-157.

[16] Radonjic-Hoesli S, Hofmeier KS, Micaletto S, Schmid-Grendelmeier P, Bircher A, Simon D. Urticaria and angioedema: An update on classification and pathogenesis. *Clin Rev Allergy Immunol* 2018; **54**(1): 88-101.

[17] Kanani A, Schellenberg R, Warrington R. Urticaria and angioedema. *Allergy Ashtma Clin Immunol* 2011; **7**(1): 9.

[18] Yoshikawa H, Wu Z, Kimata I, Iseki M, Ali IK, Hossain MB, et al. Polymerase chain reaction-based genotype classification among human *Blastocystis hominis* populations isolated from different countries. *Parasitol Res* 2004; **92**(1): 22-29.

[19] Scicluna SM, Tawari B, Clark CG. DNA barcoding of *Blastocystis*. *Protist* 2006; **157**(1): 77-85.

[20] Kumar S, Stecher G, Tamura K. MEGA7: Molecular evolutionary genetics analysis version 7.0 for bigger data sets. *Mol Biol Evol* 2016; **33**(7): 1870-1874.

[21] Hameed DM, Hassanin OM, Zuel-Fakkar NM. Association of *Blastocystis hominis* genetic subtypes with urticaria. *Parasitol Res* 2011; **108**(3): 553-560.

[22] Casero RD, Mongi F, Sánchez A, Ramírez JD. *Blastocystis* and urticaria: Examination of subtypes and morphotypes in an unusual clinical manifestation. *Acta Trop* 2015; **148**: 156-161.

[23] Zuel-Fakkar NM, Abdel Hameed DM, Hassanin OM. Study of *Blastocystis hominis* isolates in urticaria: A case-control study. *Clin Exp Dermatol* 2011; **36**(8): 908-910.

[24] Clark CG. Extensive genetic diversity in *Blastocystis hominis*. *Mol Biochem Parasitol* 1997; **87**(1): 79-93.

[25] Kaneda Y, Horiki N, Cheng XJ, Fujita Y, Maruyama M, Tachibana H. Ribodemes of *Blastocystis hominis* isolated in Japan. *Am J Trop Med* Hyg 2001; **65**(4): 393-396.

[26] Puthia MK, Lu J, Tan KS. *Blastocystis ratti* contains cysteine proteases that mediate interleukin-8 response from human intestinal epithelial cells in an NF- kappaB-dependent manner. *Eukaryot Cell* 2008; **7**(3): 435-443.

[27] Yan Y, Su S, Lai R, Liao H, Ye J, Li X, et al. Genetic variability of *Blastocystis hominis* isolates in China. *Parasitol Res* 2006; **99**(5): 597-601.

[28] El Safadi D, Meloni D, Poirier P, Osman M, Cian A, Gaayeb L, et al. Molecular epidemiology of *Blastocystis* in Lebanon and correlation between subtype 1 and gastrointestinal symptoms. *Am J Trop Med Hyg* 2013; **88**(6): 1203-1206.

[29] Stensvold CR, Christiansen DB, Olsen KE, Nielsen HV. *Blastocystis* sp. subtype 4 is common in Danish *Blastocystis*-positive patients presenting with acute diarrhea. *Am J Trop Med Hyg* 2011; **84**(6): 883-885.

[30] Lepczy ska M, Chen WC, Dzika E. Mysterious chronic urticaria caused by *Blastocystis* spp.? *Int J Dermatol* 2016; **55**(3): 259-266.

[31] Gupta R, Parsi K. Chronic urticaria due to *Blastocystis hominis*. *Australas J Dermatol* 2006; **47**(2): 117-119.

[32] Katsarou-Katsari A, Vassalos CM, Tzanetou K, Spanakos G, Papadopoulou C, Vakalis N. Acute urticaria associated with amoeboid forms of *Blastocystis* sp. subtype 3. *Acta Derm Venereol* 2008; **88**(1): 80-81.